Quoting from the March 1st article by Ed Sealover:
"The state government is looking at becoming a provider — possibly the sole provider — of children’s vaccines in Colorado, which worries bioscience companies and some doctors...
...Because there are tiered prices for biotech companies to sell to public and private providers of vaccines in the United States — with private-market prices being higher — the state becoming a major purchaser could lower revenue, said Dan Stinchcomb, CEO of vaccine developer Inviragen Inc. of Fort Collins. That would make it harder for startups working on new vaccines to find capital funding and could lead to fewer companies working to develop better vaccines, said April Giles, president/CEO of the Colorado Bioscience Association.
Link to the full article (subscription required for full access)